Product Images Losartan Potassium 50 Mg

This appears to be a chart or a graph related to a study of patients using either Atenolol or Losartan potassium. The chart shows the adjusted risk reduction percentage and the p-value for the primary endpoint. Additionally, the study timeline is represented in months up until 66 months. However, the chart seems incomplete or lacks context to fully evaluate the purpose of the study and its findings.*

This is likely a graph or chart displaying the percentage of patients who had a fatal or non-fatal stroke while taking two different medications - Atenolol and Losartan potassium ot. The x-axis of the graph denotes study month, with data points at every 6-month interval up to 66 months. However, without more context or additional information, it is not possible to determine more specifically what this graph represents.*

The provided text is a table showing the results of a study on the effectiveness of two medications (Losartan and Atenolol) for preventing primary composite stroke. The table displays the number of events and rates of stroke in different patient groups based on factors such as age, gender, race, diabetes, and history of cardiovascular disease. It also shows the hazard ratios and confidence intervals for each group to compare the effectiveness of the two medications.*

The text indicates a report or a study discussing risk reduction of an event by 16.1%. The value of 'p' is given as 0.022. The remaining text seems to be a part of a table or graph, displaying the percentages of patients with an event, with 40 and 20 being possible values.*

This is a description of a medication named Losartan Potassium USP in tablet form. The tablets come in a bottle of 90 and each tablet contains 50 mg of the active ingredient, Losartan Potassium USP. The tablets have a shelf life until September 2022 and should be taken as advised. The medication is produced by a pharmaceutical company based in Oklahoma City. The label advises the user to contact a doctor if side effects occur and provides the FDA hotline for reporting side effects. The text also includes information about the lot and reorder number. The description does not include information on the medication's purpose or indications.*